Welcome to Paid Research Studies




  • Condition:   Penile Cancer
    Interventions:   Drug: Arm A: Atezolizumab and Radiotherapy;   Drug: Arm B: Atezolizumab
    Sponsors:   The Netherlands Cancer Institute;   Hoffmann-La Roche
    Recruiting

  • Conditions:   Penile Cancer;   Squamous Carcinoma
    Intervention:   Drug: Chemotherapy TIP
    Sponsors:   UNICANCER;   National Cancer Institute, France
    Recruiting

  • Conditions:   Penile Cancer;   Advanced Cancer;   Metastatic Cancer
    Interventions:   Drug: Avelumab;   Other: Best Supportive Care
    Sponsor:   University Health Network, Toronto
    Recruiting

  • Conditions:   Penile Cancer;   Penile Neoplasms;   Penile Squamous Cell Carcinoma
    Intervention:   Drug: Avelumab
    Sponsors:   Centre Hospitalier Universitaire de Besancon;   Pfizer
    Recruiting

  • Condition:   Squamous Cell Carcinoma of the Penis, Usual Type
    Interventions:   Procedure: ILND - Inguinal Lymph Node Dissection;   Drug: Paclitaxel;   Drug: Ifosfamide;   Drug: Cisplatin;   Radiation: Intensity modulated radiation treatment (IMRT);   Procedure: Prophylactic PLND - pelvic lymph node dissection
    Sponsors:   Institute of Cancer Research, United Kingdom;   ECOG-ACRIN Cancer Research Group;   Canadian Cancer Trials Group
    Recruiting

  • Conditions:   Cervical Cancer;   Anal Cancer;   Penile Cancer
    Intervention:   Behavioral: Framed HPV vaccination messages
    Sponsor:   University of Maryland, College Park
    Not yet recruiting

  • Conditions:   Human Papilloma Virus;   Cervical Cancer;   Oropharyngeal Cancer;   Anal Cancer;   Vaginal or Penile Cancer
    Intervention:   Drug: M7824
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Advanced Clear Cell Renal Cell Carcinoma;   Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant;   Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant;   Kidney Small Cell Carcinoma;   Metastatic Bladder Small Cell Carcinoma;   Metastatic Bladder Squamous Cell Carcinoma;   Metastatic Bladder Urothelial Carcinoma;   Metastatic Kidney Medullary Carcinoma;   Metastatic Malignant Genitourinary System Neoplasm;   Metastatic Malignant Neoplasm in the Bone;   Metastatic Penile Carcinoma;   Metastatic Renal Cell Carcinoma;   Metastatic Renal Pelvis Urothelial Carcinoma;   Metastatic Sarcomatoid Renal Cell Carcinoma;   Metastatic Ureter Urothelial Carcinoma;   Metastatic Urethral Urothelial Carcinoma;   Progressive Disease;   Squamous Cell Carcinoma of the Penis;   Stage III Bladder Adenocarcinoma AJCC v6 and v7;   Stage III Bladder Squamous Cell Carcinoma AJCC v6 and v7;   Stage III Bladder Urothelial Carcinoma AJCC v6 and v7;   Stage III Penile Cancer AJCC v7;   Stage III Renal Cell Cancer AJCC v7;   Stage III Renal Pelvis Cancer AJCC v7;   Stage III Ureter Cancer AJCC v7;   Stage III Urethral Cancer AJCC v7;   Stage IIIa Penile Cancer AJCC v7;   Stage IIIb Penile Cancer AJCC v7;   Stage IV Bladder Adenocarcinoma AJCC v7;   Stage IV Bladder Squamous Cell Carcinoma AJCC v7;   Stage IV Bladder Urothelial Carcinoma AJCC v7;   Stage IV Penile Cancer AJCC v7;   Stage IV Renal Cell Cancer AJCC v7;   Stage IV Renal Pelvis Cancer AJCC v7;   Stage IV Ureter Cancer AJCC v7;   Stage IV Urethral Cancer AJCC v7
    Interventions:   Drug: Cabozantinib;   Drug: Cabozantinib S-malate;   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Bladder Adenocarcinoma;   Bladder Mixed Adenocarcinoma;   Bladder Small Cell Carcinoma;   Bladder Squamous Cell Carcinoma;   Bone Lesion;   Chromophobe Renal Cell Carcinoma;   Infiltrating Bladder Lymphoepithelioma-Like Carcinoma;   Infiltrating Bladder Urothelial Carcinoma;   Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant;   Infiltrating Bladder Urothelial Carcinoma With Giant Cells;   Infiltrating Bladder Urothelial Carcinoma, Nested Variant;   Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant;   Kidney Medullary Carcinoma;   Large Cell Neuroendocrine Carcinoma;   Metastatic Bladder Carcinoma;   Metastatic Bladder Large Cell Neuroendocrine Carcinoma;   Metastatic Bladder Small Cell Carcinoma;   Metastatic Bladder Squamous Cell Carcinoma;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Lipid-Rich Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant;   Metastatic Kidney Medullary Carcinoma;   Metastatic Malignant Genitourinary System Neoplasm;   Metastatic Penile Carcinoma;   Metastatic Prostate Small Cell Carcinoma;   Metastatic Sarcomatoid Renal Cell Carcinoma;   Papillary Renal Cell Carcinoma;   Sarcomatoid Renal Cell Carcinoma;   Stage IV Bladder Cancer AJCC v8;   Stage IV Penile Cancer AJCC v8;   Stage IV Prostate Cancer AJCC v8;   Stage IV Renal Cell Cancer AJCC v8;   Stage IVA Bladder Cancer AJCC v8;   Stage IVA Prostate Cancer AJCC v8;   Stage IVB Bladder Cancer AJCC v8;   Stage IVB Prostate Cancer AJCC v8;   Testicular Leydig Cell Tumor;   Testicular Sertoli Cell Tumor
    Interventions:   Drug: Cabozantinib;   Drug: Cabozantinib S-malate;   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Human Papillomavirus-16 Positive;   Human Papillomavirus-18 Positive;   Metastatic Malignant Neoplasm;   Recurrent Anal Canal Carcinoma;   Recurrent Cervical Carcinoma;   Recurrent Malignant Neoplasm;   Recurrent Penile Carcinoma;   Recurrent Vaginal Carcinoma;   Recurrent Vulvar Carcinoma;   Refractory Malignant Neoplasm;   Stage IV Anal Cancer AJCC v8;   Stage IV Cervical Cancer AJCC v8;   Stage IV Penile Cancer AJCC v8;   Stage IV Vaginal Cancer AJCC v8;   Stage IV Vulvar Cancer AJCC v8;   Stage IVA Cervical Cancer AJCC v8;   Stage IVA Vaginal Cancer AJCC v8;   Stage IVA Vulvar Cancer AJCC v8;   Stage IVB Cervical Cancer AJCC v8;   Stage IVB Vaginal Cancer AJCC v8;   Stage IVB Vulvar Cancer AJCC v8
    Interventions:   Biological: DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457;   Biological: Durvalumab
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Carcinoma of Unknown Primary Origin;   Kidney Medullary Carcinoma;   Malignant Germ Cell Tumor;   Metastatic Adrenal Gland Pheochromocytoma;   Metastatic Malignant Solid Neoplasm;   Metastatic Paraganglioma;   Metastatic Penile Carcinoma;   Paraganglioma;   Skin Squamous Cell Carcinoma;   Small Cell Carcinoma;   Stage IV Adrenal Cortex Carcinoma AJCC v7;   Stage IV Penile Cancer AJCC v7;   Stage IV Renal Cell Cancer AJCC v7;   Unresectable Solid Neoplasm;   Vascular Neoplasm
    Interventions:   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab;   Other: Questionnaire Administration
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Genitourinary Cancer;   Adrenocortical Carcinoma;   Non-urothelial Bladder;   Non-urothelial Upper Tract;   Penile Cancer;   Non-adenocarcinoma Prostate Cancer;   Refractory Germ-cell
    Interventions:   Drug: Ipilimumab;   Drug: Nivolumab
    Sponsors:   Dana-Farber Cancer Institute;   Bristol-Myers Squibb
    Recruiting

  • Conditions:   Adenocarcinoma;   Adenocystic Carcinoma;   Anal Cancer;   Appendix Cancer;   Brain Tumor;   Glioblastoma;   Astrocytoma;   Bile Duct Cancer;   Cholangiocarcinoma;   Bladder Cancer;   Bone Cancer;   Synovial Sarcoma;   Chondrosarcoma;   Liposarcoma;   Sarcoma, Kaposi;   Sarcoma,Soft Tissue;   Sarcoma;   Osteosarcoma;   CNS Cancer;   Brain Stem Neoplasms;   Breast Cancer;   Cervical Cancer;   Colorectal Cancer;   Rectal Cancer;   Colon Cancer;   Esophageal Cancer;   Esophagus Cancer;   Cancer of Colon;   Pancreatic Cancer;   Cancer of Pancreas;   Testis Cancer;   Testicular Cancer;   Ureter Cancer;   Renal Cell Carcinoma;   Kidney Cancer;   Gestational Trophoblastic Tumor;   Head and Neck Neoplasms;   Parotid Tumor;   Larynx Cancer;   Tongue Cancer;   Pharynx Cancer;   Salivary Gland Cancer;   Acute Myeloid Leukemia;   Chronic Myeloid Leukemia;   Acute Lymphoblastic Leukemia;   Multiple Myeloma;   Non Hodgkin Lymphoma;   Carcinoid Tumor;   Lung Cancer;   Neuroendocrine Tumors;   Mesothelioma;   Thyroid Cancer;   Parathyroid Neoplasms;   Adrenal Cancer;   Small Bowel Cancer;   Stomach Cancer;   Liver Cancer;   Hepatic Cancer;   Melanoma;   Skin Cancer;   Unknown Primary Tumors;   Uterine Cancer;   Fallopian Tube Cancer;   Ovarian Cancer;   Prostate Cancer;   Vaginal Cancer;   Penile Cancer;   Vulvar Cancer;   Waldenstrom Macroglobulinemia;   Cancer, Advanced;   Thymus Cancer;   Nasopharyngeal Carcinoma;   Multiple Endocrine Neoplasia;   Pheochromocytoma;   Small Cell Carcinoma;   Pulmonary Carcinoma
    Interventions:   Diagnostic Test: Testing: Genome;   Diagnostic Test: Testing: Transcriptome;   Diagnostic Test: Testing: Proteome;   Drug: Treatment: CAR-T
    Sponsor:   Taproot Health
    Not yet recruiting

  • Conditions:   Pancreatic Cancer;   Thyroid Cancer;   Lung Cancer;   Esophageal Cancer;   Thymus Cancer;   Colon Cancer;   Rectal Cancer;   GIST;   Anal Cancer;   Bile Duct Cancer;   Duodenal Cancer;   Gallbladder Cancer;   Gastric Cancer;   Liver Cancer;   Small Intestine Cancer;   Peritoneal Surface Malignancies;   Familial Adenomatous Polyposis;   Lynch Syndrome;   Bladder Cancer;   Kidney Cancer;   Penile Cancer;   Prostate Cancer;   Testicular Cancer;   Ureter Cancer;   Urethral Cancer;   Hypopharyngeal Cancer;   Laryngeal Cancer;   Lip Cancer;   Oral Cavity Cancer;   Nasopharyngeal Cancer;   Oropharyngeal Cancer;   Paranasal Sinus Cancer;   Nasal Cavity Cancer;   Salivary Gland Cancer;   Skin Cancer;   CNS Tumor;   CNS Cancer;   Mesothelioma;   Breast Cancer;   Leukemia;   Melanoma;   Sarcoma;   Unknown Primary Tumor;   Multiple Myeloma;   Ovarian Cancer;   Endometrial Cancer;   Vaginal Cancer;   Neuroendocrine Tumors;   Plasma Cell Dyscrasia
    Intervention:  
    Sponsor:   University of Nebraska
    Recruiting

  • Conditions:   Human Papillomavirus-Related Carcinoma;   Human Papillomavirus Positive Oropharyngeal Carcinoma;   Human Papillomavirus Positive Cervical Carcinoma;   Human Papillomavirus Positive Anal Carcinoma;   Human Papillomavirus Positive Vulvar Carcinoma;   Human Papillomavirus Positive Penile Carcinoma
    Interventions:   Genetic: HPV Specific T Cells;   Drug: Cytoxan;   Drug: Fludarabine;   Biological: Nivolumab
    Sponsors:   Baylor College of Medicine;   Center for Cell and Gene Therapy, Baylor College of Medicine;   The Methodist Hospital System
    Recruiting

  • Condition:   Penile Squamous Cell Carcinoma
    Intervention:   Drug: Pembrolizumab
    Sponsors:   University of Alabama at Birmingham;   Merck Sharp & Dohme Corp.
    Recruiting

  • Conditions:   Acinar Cell Carcinoma;   Adenoid Cystic Carcinoma;   Adrenal Cortex Carcinoma;   Adrenal Gland Pheochromocytoma;   Anal Canal Neuroendocrine Carcinoma;   Anal Canal Undifferentiated Carcinoma;   Angiosarcoma;   Apocrine Neoplasm;   Appendix Mucinous Adenocarcinoma;   Bartholin Gland Transitional Cell Carcinoma;   Basal Cell Carcinoma;   Bladder Adenocarcinoma;   Cervical Adenocarcinoma;   Cervical Clear Cell Adenocarcinoma;   Cholangiocarcinoma;   Chordoma;   Colorectal Squamous Cell Carcinoma;   Desmoid-Type Fibromatosis;   Endometrial Transitional Cell Carcinoma;   Endometrioid Adenocarcinoma;   Esophageal Neuroendocrine Carcinoma;   Esophageal Undifferentiated Carcinoma;   Extrahepatic Bile Duct Carcinoma;   Extramammary Paget Disease;   Fallopian Tube Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Fibromyxoid Tumor;   Gallbladder Carcinoma;   Gastric Neuroendocrine Carcinoma;   Gastric Squamous Cell Carcinoma;   Gastric Undifferentiated Carcinoma;   Gastrointestinal Stromal Tumor;   Gestational Trophoblastic Tumor;   Giant Cell Carcinoma;   Intestinal Neuroendocrine Carcinoma;   Intrahepatic Cholangiocarcinoma;   Lung Carcinoid Tumor;   Lung Sarcomatoid Carcinoma;   Major Salivary Gland Carcinoma;   Malignant Odontogenic Neoplasm;   Malignant Peripheral Nerve Sheath Tumor;   Malignant Testicular Sex Cord-Stromal Tumor;   Metaplastic Breast Carcinoma;   Metastatic Malignant Neoplasm of Unknown Primary;   Minimally Invasive Lung Adenocarcinoma;   Mixed Mesodermal (Mullerian) Tumor;   Mucinous Adenocarcinoma;   Mucinous Cystadenocarcinoma;   Nasal Cavity Adenocarcinoma;   Nasal Cavity Carcinoma;   Nasopharyngeal Carcinoma;   Nasopharyngeal Papillary Adenocarcinoma;   Nasopharyngeal Undifferentiated Carcinoma;   Oral Cavity Carcinoma;   Oropharyngeal Undifferentiated Carcinoma;   Ovarian Adenocarcinoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Germ Cell Tumor;   Ovarian Mucinous Adenocarcinoma;   Ovarian Squamous Cell Carcinoma;   Ovarian Transitional Cell Carcinoma;   Pancreatic Acinar Cell Carcinoma;   Pancreatic Neuroendocrine Carcinoma;   Paraganglioma;   Paranasal Sinus Adenocarcinoma;   Paranasal Sinus Carcinoma;   Parathyroid Gland Carcinoma;   PEComa;   Peritoneal Mesothelioma;   Pituitary Gland Carcinoma;   Placental Choriocarcinoma;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Pseudomyxoma Peritonei;   Rare Disorder;   Scrotal Squamous Cell Carcinoma;   Seminal Vesicle Adenocarcinoma;   Seminoma;   Serous Cystadenocarcinoma;   Small Intestinal Adenocarcinoma;   Small Intestinal Squamous Cell Carcinoma;   Solid Neoplasm;   Spindle Cell Neoplasm;   Squamous Cell Carcinoma of the Penis;   Teratoma With Somatic-Type Malignancy;   Testicular Non-Seminomatous Germ Cell Tumor;   Thyroid Gland Carcinoma;   Tracheal Carcinoma;   Transitional Cell Carcinoma;   Ureter Adenocarcinoma;   Ureter Squamous Cell Carcinoma;   Urethral Adenocarcinoma;   Urethral Squamous Cell Carcinoma;   Vaginal Adenocarcinoma;   Vaginal Squamous Cell Carcinoma, Not Otherwise Specified;   Vulvar Carcinoma
    Interventions:   Procedure: Biospecimen Collection;   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Cancer That is Associated With a Chronic Viral Infection;   p16 Positive SCCHN;   Squamous Cell Carcinoma of the Cervix;   p16 Positive Squamous Cell Carcinoma of the Vagina or Vulva;   p16 Positive Squamous Cell Carcinoma of the Penis;   p16 Positive Squamous Cell Carcinoma of the Anus or Anal Canal;   EBER Positive NPC;   EBER Positive Hodgkins and Non-hodgkins Lymphona
    Interventions:   Drug: Valproic Acid;   Biological: Avelumab
    Sponsors:   AHS Cancer Control Alberta;   EMD Serono
    Recruiting

  • Conditions:   Appendix Adenocarcinoma;   Human Papillomavirus-Related Anal Squamous Cell Carcinoma;   Human Papillomavirus-Related Cervical Squamous Cell Carcinoma;   Human Papillomavirus-Related Squamous Cell Carcinoma of the Penis;   Human Papillomavirus-Related Vulvar Squamous Cell Carcinoma;   Neuroendocrine Carcinoma;   Pancreatic Neuroendocrine Tumor;   Recurrent Merkel Cell Carcinoma;   Recurrent Nasopharynx Carcinoma;   Recurrent Peritoneal Malignant Mesothelioma;   Recurrent Pleural Malignant Mesothelioma;   Stage III Merkel Cell Carcinoma AJCC v7;   Stage III Nasopharyngeal Carcinoma AJCC v7;   Stage III Pleural Malignant Mesothelioma AJCC v7;   Stage IV Merkel Cell Carcinoma AJCC v7;   Stage IV Nasopharyngeal Carcinoma AJCC v7;   Stage IV Pleural Malignant Mesothelioma AJCC v7;   Stage IVA Nasopharyngeal Carcinoma AJCC v7;   Stage IVB Nasopharyngeal Carcinoma AJCC v7;   Stage IVC Nasopharyngeal Carcinoma AJCC v7;   Vaginal Squamous Cell Carcinoma, Not Otherwise Specified
    Interventions:   Drug: Atezolizumab;   Biological: Bevacizumab;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Gastrointestinal Stromal Tumors;   Advanced Systemic Mastocytosis;   Advanced Cancers
    Intervention:   Drug: DCC-2618
    Sponsor:   Deciphera Pharmaceuticals LLC
    Recruiting

  • Condition:   Malignant Neoplasms of Male Genital Organs
    Interventions:   Procedure: Caudal Nerve Block (CNB);   Drug: Ropivacaine;   Drug: Epinephrine;   Drug: Decadron;   Drug: Clonidine;   Drug: Propofol;   Behavioral: Phone Call
    Sponsors:   M.D. Anderson Cancer Center;   Merck Sharp & Dohme Corp.
    Recruiting